Posted by Michael Wonder on 10 Jan 2025
ViGeneron announces FDA rare paediatric disease designation for VG901
8 January 2025 - ViGeneron today announced two important milestones for its novel gene therapy candidate VG901, to treat patients with retinitis pigmentosa caused by mutations in the CNGA1 gene.
The US FDA has granted rare paediatric disease designation to VG901.
